Roche Holding AG
corporate_fare Company Profile
Roche Holding AG (OTC:RHHBY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for RHHBY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above.
Recent high-impact activity:
- Gazyva Wins First-Ever FDA Approval for Primary Membranous Nephropathy
- Divarasib Cuts Death Risk 44% vs Standard KRAS Drugs in Phase III Lung Cancer Trial
- Sefaxersen Cuts Proteinuria 43% in Phase III IgA Nephropathy Trial
- Roche Q3 Revenue Tops Consensus at CHF16.13B, Guidance Confirmed
- FDA Approves First At-Home Subcutaneous Treatment for Thyroid Eye Disease
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 2,892,550 shares in RHHBY as of the October 30, 2026 settlement, a 5.2% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 12.7% of RHHBY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.